唑类耐药曲霉病:流行病学、分子机制与治疗
本文综述烟曲霉仍为各类肺部综合征最常见菌种,黄曲霉常见于过敏性鼻窦炎、术后曲霉病与真菌性角膜炎。三唑类是曲霉感染治疗与预防的主要手段,烟曲霉唑类耐药上升构成有效管理的重大挑战。早期研究提示非cyp51突变与cyp51A基因改变共同导致耐药表型,本文概述耐药曲霉病的规模、耐药机制及治疗选择。
要点
- 烟曲霉是各类肺部综合征最常见菌种,黄曲霉常见于过敏性鼻窦炎、术后曲霉病和真菌性角膜炎。
- 三唑类是曲霉感染治疗和预防的主要手段,烟曲霉唑类耐药上升使有效管理面临重大挑战。
- 非cyp51突变与cyp51A基因改变共同参与烟曲霉唑类耐药表型的形成。
核心结论
- 烟曲霉唑类耐药已成为曲霉病有效管理的重大挑战。
- 非cyp51突变与cyp51A基因改变共同导致烟曲霉唑类耐药表型。
主要发现
- 烟曲霉仍是所有肺部综合征中最常见的曲霉菌种。
- 黄曲霉是过敏性鼻窦炎、术后曲霉病和真菌性角膜炎的常见病因。
- 曲霉感染表现包括侵袭性曲霉病、慢性肺曲霉病和支气管炎。
- 吸入曲霉的过敏性表现包括过敏性支气管肺曲霉病和伴真菌致敏的重症哮喘。
临床怎么用
- 三唑类是抗曲霉感染治疗与预防的主要手段。
- 需关注烟曲霉唑类耐药对治疗效果的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aspergillus fumigatus remains the most common species in all pulmonary syndromes, followed by Aspergillus flavus which is a common cause of allergic rhinosinusitis, postoperative aspergillosis and fungal keratitis. The manifestations of Aspergillus infections include invasive aspergillosis, chronic pulmonary aspergillosis and bronchitis. Allergic manifestations of inhaled Aspergillus include allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. Triazoles are the mainstay of therapy against Aspergillus infections for treatment and prophylaxis. Lately, increased azole resistance in A. fumigatus has become a significant challenge in effective management of aspergillosis. Earlier studies have brought to light the contribution of non-cyp51 mutations along with alterations in cyp51A gene resulting in azole-resistant phenotypes of A. fumigatus. This review highlights the magnitude of azole-resistant aspergillosis and resistance mechanisms implicated in the development of azole-resistant A. fumigatus and address the therapeutic options available.
引用
- Chowdhary A, Sharma C, Meis JF, et al. Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment. J Infect Dis. 2017. PMID: 28911045. doi:10.1093/infdis/jix210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。